Well Daan Van Sells 2,400 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Key Points

• Well Daan Van sold 2,400 shares of SOPHiA GENETICS on April 10 at an average price of $4.67 under a pre-arranged Rule 10b5-1 plan to cover tax withholding, leaving him with 346,420 shares (a 0.69% reduction).
• He made multiple sales between March 19 and April 10 totaling 10,638 shares for roughly $50,930 in proceeds, reflecting continued disposition of vested equity awards.
• SOPH traded up about 2.3% to $4.96; the company reported Q results with EPS of -$0.28 (miss) and a slight revenue beat, has a market cap near $340M, and carries a consensus "Hold" rating with a $7 target.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Well Daan Van sold 2,400 shares of the firm's stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $4.67, for a total transaction of $11,208.00. Following the transaction, the insider owned 346,420 shares of the company's stock, valued at approximately $1,617,781.40. The trade was a 0.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Well Daan Van also recently made the following trade(s):

• On Thursday, April 9th, Well Daan Van sold 1,988 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,423.12.
• On Wednesday, April 8th, Well Daan Van sold 2,861 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total transaction of $13,875.85.
• On Monday, April 6th, Well Daan Van sold 2,705 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.86, for a total transaction of $13,146.30.
• On Thursday, March 19th, Well Daan Van sold 684 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total transaction of $3,276.36.

SOPHiA GENETICS Trading Up 2.3%

SOPHiA GENETICS stock traded up $0.11 during mid-day trading on Tuesday, hitting $4.96. 148,768 shares of the stock were exchanged, compared to its average volume of 183,135. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. SOPHiA GENETICS SA has a 12 month low of $2.58 and a 12 month high of $5.70. The firm's fifty day simple moving average is $4.74 and its two-hundred day simple moving average is $4.71. The stock has a market capitalization of $339.71 million, a price-to-earnings ratio of -9.73 and a beta of 1.04.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The firm had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. Analysts forecast that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Analyst Ratings Changes

SOPH has been the subject of several research analyst reports. Guggenheim lifted their price objective on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a "buy" rating in a research note on Monday, January 26th. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Finally, BTIG Research reiterated a "buy" rating and issued a $7.00 price objective on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $7.00.

Institutional Trading of SOPHiA GENETICS

Several hedge funds have recently modified their holdings of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock valued at $25,341,000 after acquiring an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC increased its stake in shares of SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock valued at $11,529,000 after acquiring an additional 1,481,636 shares in the last quarter. Alta Wealth Advisors LLC bought a new stake in shares of SOPHiA GENETICS in the 3rd quarter valued at $6,708,000. Royce & Associates LP bought a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at $2,009,000. Finally, 1492 Capital Management LLC bought a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at $973,000. Institutional investors own 31.59% of the company's stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.